AMCP’s Science & Innovation Theaters provide a structured focus for participants to gain information on specific products, therapeutic areas and/or disease states in presentations provided by company designated presenters. Theaters take place in The Exchange on Wednesday, October 24.
AMCP Science & Innovation Theaters with a include preapproval information exchange information. Subject to federal laws and regulations, attendance at these sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in the area of health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. For more information, visit our website.
ALKS 5461 - Investigational Product for the adjunctive treatment of Major Depressive Disorder (MDD)
Provided by Alkermes Inc.
12:00pm-12:30pm / Theater #1
This presentation will provide information on ALKS 5461 - an investigational product developed by Alkermes and currently under review by the FDA for the proposed indication of adjunctive treatment of Major Depressive Disorder (MDD). An overview of investigational product information will be provided, including a description of clinical program and study results.
Elizabeth Dorn, PhD
Medical Director, Medical Affairs
A New Migraine Therapy for Patients
Provided by Amgen, Inc.
12:00pm-12:30pm / Theater #2
This theater will provide an overview of a newly approved treatment for prevention of migraine in adults. The program includes a conversation about the approved indication, important safety information, key findings from clinical trials, and other important prescribing information. This program will also explore the clinical development of the treatment and two patient cases—one an episodic migraine patient and the other a chronic migraine patient.
Timothy R Smith, MD, RPh
President & CEO
St Louis, MO
Acute Migraine: Current and Investigational Treatment Landscape
Provided by Allergan
12:45pm-1:15pm / Theater #1
This session will address emerging issues in the changing migraine landscape, including analysis of current treatment utilization for acute migraine symptoms, the unintended consequences of mismanagement of those symptoms, and investigational products that may address challenges with current treatment options.
Patricia Jacob, PharmD, MS
Allergan; Managed Care Scientific Director
Value is in the Eye of the Contract Holder: Data Analytics Behind Value-Based Contract
Provided by Amgen, Inc.
12:45pm-1:15pm / Theater #2
Value based contracts can take on many forms and their conceptual framework has been previously presented at various conferences; manufacturers may utilize value based contracts to support and/or demonstrate a product’s value to health plans.
This presentation will focus on how to translate an interest in value based contracting into successful execution. It will address questions such as: “Who should be involved during the value based contracting process?”, “What types of therapeutic areas and/or products may be suitable for value based contracts?”, “What capabilities and data do I need to enter into a value based contract?”, and “Who analyzes the data to determine the results of the contract?”
Come listen as we look under the hood and take you through the Who, What, Why, When, and How value based contracts are developed and implemented.
David J. Harrison, PhD
Director, Global Health Economics
Patrick P. Gleason, PharmD, BCPS, FCCP, FAMCP
Senior Director, Health Outcomes
Prime Therapeutics, LLC
The Role of VASCEPA® (icosapent ethyl): Topline Results from REDUCE-IT™
Provided by Amarin Pharma, Inc.
1:30pm-2:00pm / Theater #1
A brief overview of high TGs as a marker of CV risk and a review of topline results from the VASCEPA CV outcomes trial, REDUCE-IT™.
Dean A. Bramlet, MD, FACC, FNLA, FAHA
Cardiovascular Diagnostic Center
Emerging Therapeutic Option in Gene Replacement Therapy
Provided by AveXis, Inc.
1:30pm-2:00pm / Theater #2
This presentation will describe the data on emerging therapeutic option in gene replacement therapy with a focus on a nonreplicating adeno-associated virus vector carrying a self-complimentary SMN transgene (sc.AAV9.CB.SMN [self-complementary adeno-associated viral serotype 9]) currently in Phase 3 for spinal muscular atrophy (SMA).
Samiah Al-Zaidy, MD
Medical Consultant for AveXis